The particulars: early satiety · six · semaglutide.
This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.
What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.
What is the correct sequence, and where is the step that people usually skip?
Week 6 is day 42: on a four-week ladder that is week 2 of dose step 2, and — at the seven-day half-life this class runs on — 6 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 42 is 1 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 2 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Early satiety is the mechanism rather than a side effect of it — delayed gastric emptying is the intended pharmacology — so the question the week number helps with is whether it is proportionate, not whether it is expected. Dose decisions are made under supervision, and nothing here is medical advice.
The honest answer is that the first eight weeks are the hard part and that most people who get through them stop having the conversation.
Symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
| Event | Active arm | Placebo arm | Timing |
|---|---|---|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Concretely, fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
Research-use compounds are not approved for human use.
Smaller meals, less fat, fluids between rather than with. In that order.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe short version: dose-related, escalation-concentrated, mostly attenuating except for constipation, and manageable by titration pace more than anything else.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
To be exact about it, reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.
Most people who report these effects continue. The discontinuation rate is low.
edited 16 Feb 2026 by v_ramaswamy — expanded the table to cover the lower concentration
Answering this needs the titration history, because going faster than the schedule is the single largest modifiable factor.
Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.
The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Everything except constipation attenuates. Plan differently for that one.
This is the group of effects that drives almost all discontinuation in the trial programmes.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.
New symptoms at a stable dose after months need a different explanation.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.